StoxAlkem Laboratories vs Gland Pharma: share price & financials comparison
NSE: ALKEM vs GLAND · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Alkem Laboratories vs Gland Pharma at a glance
Alkem Laboratories (ALKEM) has a market capitalisation of ₹61,138 Cr, against ₹55,016 Cr for Gland Pharma (GLAND). Over the past year Gland Pharma has returned +74.4%, compared with -9.7% for Alkem Laboratories. On valuation, Alkem Laboratories trades at a lower P/E of 29.6 versus 44.5. Alkem Laboratories earns a higher return on equity (13.9% vs 11.6%). Alkem Laboratories comes out ahead on size and valuation. Gland Pharma comes out ahead on profitability, growth, financial health, momentum and technicals. Across the scored metrics below, Alkem Laboratories leads on 6 and Gland Pharma on 11. On StoxGud's 10-point checklist, Alkem Laboratories scores 5/10 and Gland Pharma scores 8/10.
| Metric | Alkem Laboratories | Gland Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹61,138 Cr | ₹55,016 Cr |
| Revenue (latest FY) | ₹14,712 Cr | ₹6,431 Cr |
| Net profit (latest FY) | ₹2,302 Cr | ₹1,027 Cr |
| Valuation | ||
| P/E | 29.6 | 44.5 |
| P/B | 4.11 | 5.15 |
| Dividend yield | 1.00% | 0.54% |
| Profitability | ||
| Return on equity | 13.9% | 11.6% |
| Net profit margin | 13.2% | 17.5% |
| Operating margin | 20.1% | 27.2% |
| Growth | ||
| Revenue growth (YoY) | +13.8% | +23.3% |
| Net profit growth (YoY) | -11.7% | +58.3% |
| Revenue CAGR (multi-year) | +9.9% | +13.2% |
| Financial health | ||
| Debt to equity | 0.13 | 0.02 |
| Momentum | ||
| 1-month return | -2.6% | +7.9% |
| 1-year return | -9.7% | +74.4% |
| 3-year CAGR | +5.9% | +27.0% |
| 5-year CAGR | +7.3% | -1.7% |
| 10-year CAGR | +12.0% | — |
| Distance from 52W high | -13.2% | +0.0% |
| Technicals | ||
| RSI (14) | 59 | 88 |
| Price vs 200-day avg | -5.6% | +42.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Alkem Laboratories | Gland Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 5/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Alkem Laboratories or Gland Pharma?
Alkem Laboratories has a market cap of ₹61,138 Cr and Gland Pharma has a market cap of ₹55,016 Cr as of 13 Nov 2026.
Which has a lower P/E, Alkem Laboratories or Gland Pharma?
Alkem Laboratories has the lower P/E: Alkem Laboratories trades at 29.6 and Gland Pharma at 44.5.
Which gave better returns in the last year, Alkem Laboratories or Gland Pharma?
Gland Pharma did better: Alkem Laboratories returned -9.7% and Gland Pharma returned +74.4% over one year.
What is the difference between Alkem Laboratories and Gland Pharma?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹61,138 Cr vs ₹55,016 Cr). In the latest financial year Alkem Laboratories reported revenue of ₹14,712 Cr and Gland Pharma ₹6,431 Cr. Operating margin is 20.1% for Alkem Laboratories and 27.2% for Gland Pharma. Debt to equity is 0.13 for Alkem Laboratories and 0.02 for Gland Pharma.
Which is better, Alkem Laboratories or Gland Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Alkem Laboratories leads on 6 and Gland Pharma on 11. Alkem Laboratories is ahead on size and valuation. Gland Pharma is ahead on profitability, growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Alkem Laboratories scores 5/10 and Gland Pharma scores 8/10. This is information, not advice: consult a SEBI-registered adviser before investing.